Zhan L, Chen S, Liu Y, Lu T, Yu Z, Wang X
BMC Cancer. 2025; 25(1):351.
PMID: 40000981
PMC: 11863826.
DOI: 10.1186/s12885-025-13754-4.
Li S, Gao Y, He Y, Zhang Z
Front Neurol. 2024; 15:1371515.
PMID: 38899058
PMC: 11185937.
DOI: 10.3389/fneur.2024.1371515.
Ansari N, Salesi M
Clin Rheumatol. 2024; 43(7):2177-2186.
PMID: 38722505
DOI: 10.1007/s10067-024-06993-6.
Triantafyllias K, Bach M, Otto M, Schwarting A
Diagnostics (Basel). 2023; 13(19).
PMID: 37835860
PMC: 10573002.
DOI: 10.3390/diagnostics13193117.
Guggino G, Rizzo C, Mohammadnezhad L, Lo Pizzo M, Lentini V, Di Liberto D
RMD Open. 2023; 9(2).
PMID: 37137540
PMC: 10163598.
DOI: 10.1136/rmdopen-2022-002738.
Predicting lymphoma in Sjögren's syndrome and the pathogenetic role of parotid microenvironment through precise parotid swelling recording.
De Vita S, Isola M, Baldini C, Goules A, Chatzis L, Quartuccio L
Rheumatology (Oxford). 2022; 62(4):1586-1593.
PMID: 36063040
PMC: 10072883.
DOI: 10.1093/rheumatology/keac470.
Genome-wide association study identifies Sjögren's risk loci with functional implications in immune and glandular cells.
Khatri B, Tessneer K, Rasmussen A, Aghakhanian F, Reksten T, Adler A
Nat Commun. 2022; 13(1):4287.
PMID: 35896530
PMC: 9329286.
DOI: 10.1038/s41467-022-30773-y.
Cutaneous mucosa-associated lymphoid tissue lymphoma complicating Sjögren's syndrome: A case report and review of literature.
Liu Y, Zhu J, Huang Y, Zhang Q, Zhao L, Yu R
World J Clin Cases. 2022; 10(14):4509-4518.
PMID: 35663092
PMC: 9125287.
DOI: 10.12998/wjcc.v10.i14.4509.
Targeted Therapy for Primary Sjögren's Syndrome: Where are We Now?.
Wang B, Chen S, Li Y, Xuan J, Liu Y, Shi G
BioDrugs. 2021; 35(6):593-610.
PMID: 34731460
DOI: 10.1007/s40259-021-00505-7.
Lymphomagenesis predictors and related pathogenesis.
Ruiz-Ordonez I, Piedrahita J, Arevalo J, Agualimpia A, Tobon G
J Transl Autoimmun. 2021; 4:100098.
PMID: 33889831
PMC: 8050773.
DOI: 10.1016/j.jtauto.2021.100098.
Current State of Knowledge on Primary Sjögren's Syndrome, an Autoimmune Exocrinopathy.
Parisis D, Chivasso C, Perret J, Soyfoo M, Delporte C
J Clin Med. 2020; 9(7).
PMID: 32698400
PMC: 7408693.
DOI: 10.3390/jcm9072299.
Primary Sjogren Syndrome: Focus on Innate Immune Cells and Inflammation.
Rizzo C, Grasso G, Destro Castaniti G, Ciccia F, Guggino G
Vaccines (Basel). 2020; 8(2).
PMID: 32503132
PMC: 7349953.
DOI: 10.3390/vaccines8020272.
Prevalence and clinical presentation of lymphoproliferative disorder in patients with primary Sjögren's syndrome.
Sebastian A, Madej M, Sebastian M, Butrym A, Woytala P, Halon A
Rheumatol Int. 2020; 40(3):399-404.
PMID: 32008116
DOI: 10.1007/s00296-020-04522-7.
Invariant NKT Cells and Rheumatic Disease: Focus on Primary Sjogren Syndrome.
Rizzo C, Barbera L, Lo Pizzo M, Ciccia F, Sireci G, Guggino G
Int J Mol Sci. 2019; 20(21).
PMID: 31683641
PMC: 6862604.
DOI: 10.3390/ijms20215435.
Shared and Unique Patterns of DNA Methylation in Systemic Lupus Erythematosus and Primary Sjögren's Syndrome.
Imgenberg-Kreuz J, Carlsson Almlof J, Leonard D, Sjowall C, Syvanen A, Ronnblom L
Front Immunol. 2019; 10:1686.
PMID: 31428085
PMC: 6688520.
DOI: 10.3389/fimmu.2019.01686.
Juvenile Sjögren's Syndrome: Clinical Characteristics With Focus on Salivary Gland Ultrasonography.
Hammenfors D, Valim V, Bica B, G Pasoto S, Lilleby V, Nieto-Gonzalez J
Arthritis Care Res (Hoboken). 2019; 72(1):78-87.
PMID: 30697959
PMC: 6972604.
DOI: 10.1002/acr.23839.
Phosphatidylinositol 3-kinase delta pathway: a novel therapeutic target for Sjögren's syndrome.
Nayar S, Campos J, Smith C, Iannizzotto V, Gardner D, Colafrancesco S
Ann Rheum Dis. 2018; 78(2):249-260.
PMID: 30472652
PMC: 6352416.
DOI: 10.1136/annrheumdis-2017-212619.
B cells in the pathogenesis of primary Sjögren syndrome.
Nocturne G, Mariette X
Nat Rev Rheumatol. 2018; 14(3):133-145.
PMID: 29416129
DOI: 10.1038/nrrheum.2018.1.
Is primary Sjögren's syndrome a risk factor for malignancies different from lymphomas? What does the literature highlight about it?.
Manzo C, Kechida M
Reumatologia. 2017; 55(3):136-139.
PMID: 28769137
PMC: 5534508.
DOI: 10.5114/reum.2017.68913.
Immune Activation: Contribution to AIDS-Associated Non-Hodgkin Lymphoma.
Epeldegui M, Martinez-Maza O
For Immunopathol Dis Therap. 2017; 6(1-2):79-90.
PMID: 28702272
PMC: 5502768.
DOI: 10.1615/ForumImmunDisTher.2016014177.